Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06), Zacks reports. Astellas Pharma had a net margin of 16.01% and a return on equity of 25.79%.
Astellas Pharma Price Performance
Astellas Pharma stock traded down $0.01 during midday trading on Wednesday, reaching $16.11. The company’s stock had a trading volume of 72,842 shares, compared to its average volume of 148,332. Astellas Pharma has a 52 week low of $10.64 and a 52 week high of $17.35. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average price of $15.03 and a 200-day moving average price of $14.73. The stock has a market cap of $29.15 billion, a PE ratio of 12.26 and a beta of 0.06.
Wall Street Analysts Forecast Growth
Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.
Get Our Latest Stock Report on Astellas Pharma
Astellas Pharma Company Profile
Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.
Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.
Featured Stories
- Five stocks we like better than Astellas Pharma
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
- Bloom Energy: The Off-Grid Answer to AI’s Power Drain
- Space Race 2.0: Intuitive Machines Secures Another NASA Contract
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
